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Abstract: INTRODUCTION: Men facing prostate cancer screening and treatment need to make critical
and highly preference-sensitive decisions that involve a variety of potential benefits and risks. Shared
decision-making (SDM) is considered fundamental for ”preference-sensitive” medical decisions and it is
guideline-recommended. There is no single definition of SDM however. We systematically reviewed
the extent of SDM implementation in interventions to facilitate SDM for prostate cancer screening and
treatment. METHODS: We searched Medline Ovid, Embase (Elsevier), CINHAL (EBSCOHost), The
Cochrane Library (Wiley), PsychINFO (EBSCOHost), Scopus, clinicaltrials.gov, ISRCTN registry, the
WHO search portal, ohri.ca, opengrey.eu, Google Scholar, and the reference lists of included studies,
clinical guidelines and relevant reviews. We also contacted the authors of relevant abstracts without
available full text. We included primary peer-reviewed and grey literature of randomised controlled
trials (RCTs) reported in English, conducted in primary and specialised care, addressing interventions
aiming to facilitate SDM for prostate cancer screening and treatment. Two reviewers independently
selected studies, appraised interventions and assessed the extent of SDM implementation based on the
key features of SDM, namely information exchange, deliberation and implementation. We considered
bi-directional deliberation as a central and mandatory component of SDM. We performed a narrative
synthesis. RESULTS: Thirty-six RCTs including 19 196 randomised patients met the eligibility criteria;
they were mainly conducted in North America (n = 28). The median year of publication was 2008 (1997-
2015). Twenty-three RCTs addressed decision-making for screening, twelve for treatment and one for both
screening and treatment for prostate cancer. Bi-directional interactions between healthcare providers
and patients were verified in 31 RCTs, but only 14 fulfilled the three key SDM features, 14 had at least
”deliberation”, one had ”unclear deliberation” and two had no signs of deliberation. CONCLUSIONS:
There is significant variation in the extent of SDM implementation among studies addressing SDM for
prostate cancer screening and treatment. Further evaluation of these results on patient outcomes, a
standardised SDM definition and guidance for an effective implementation in several clinical settings are
needed.
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Summary
INTRODUCTION: Men facing prostate cancer screening
and treatment need to make critical and highly preference-
sensitive decisions that involve a variety of potential ben-
efits and risks. Shared decision-making (SDM) is consid-
ered fundamental for “preference-sensitive” medical deci-
sions and it is guideline-recommended. There is no single
definition of SDM however. We systematically reviewed
the extent of SDM implementation in interventions to facil-
itate SDM for prostate cancer screening and treatment.
METHODS: We searched Medline Ovid, Embase (Else-
vier), CINHAL (EBSCOHost), The Cochrane Library (Wi-
ley), PsychINFO (EBSCOHost), Scopus, clinicaltrials.gov,
ISRCTN registry, the WHO search portal, ohri.ca, open-
grey.eu, Google Scholar, and the reference lists of includ-
ed studies, clinical guidelines and relevant reviews. We
also contacted the authors of relevant abstracts without
available full text. We included primary peer-reviewed and
grey literature of randomised controlled trials (RCTs) re-
ported in English, conducted in primary and specialised
care, addressing interventions aiming to facilitate SDM for
prostate cancer screening and treatment. Two reviewers
independently selected studies, appraised interventions
and assessed the extent of SDM implementation based on
the key features of SDM, namely information exchange,
deliberation and implementation. We considered bi-direc-
tional deliberation as a central and mandatory component
of SDM. We performed a narrative synthesis.
RESULTS: Thirty-six RCTs including 19 196 randomised
patients met the eligibility criteria; they were mainly con-
ducted in North America (n = 28). The median year of
publication was 2008 (1997–2015). Twenty-three RCTs
addressed decision-making for screening, twelve for treat-
ment and one for both screening and treatment for
prostate cancer. Bi-directional interactions between
healthcare providers and patients were verified in 31
RCTs, but only 14 fulfilled the three key SDM features, 14
had at least “deliberation”, one had “unclear deliberation”
and two had no signs of deliberation.
CONCLUSIONS: There is significant variation in the ex-
tent of SDM implementation among studies addressing
SDM for prostate cancer screening and treatment. Further
evaluation of these results on patient outcomes, a stan-
dardised SDM definition and guidance for an effective im-
plementation in several clinical settings are needed.
Key words: systematic review, shared decision-making,
prostate cancer, screening, treatment, randomised con-
trolled trials
Introduction
Prostate cancer is one of the most serious public health
concerns relating to men’s health worldwide. The World
Health Organization (WHO) has declared prostate cancer
to be the second most commonly diagnosed type of cancer
in men, and the fifth leading cause of death due to cancer in
men worldwide [1]. It accounts for 6.6% of the total deaths
of men, and the burden is expected to increase to 1.7 mil-
lion cases and 499 000 new deaths by 2030 globally [2].
Prostate cancer incidence varies widely in the world with
higher rates (mostly) in high-income countries [1], mainly
due to the widespread use of screening tests, which have
improved early detection, but whose benefits and harms
are controversial [3, 4]. There is no consensus on the gen-
eral screening routine, including the age at which screening
should be performed [5–9], and testing has led to false-pos-
itive results and over diagnosis [10]. Furthermore, patients
often face more than one alternative treatment, which rep-
resent a variety of benefits and risks without convincing
evidence indicating a best choice [11]. The survival benefit
comes at the price of considerable morbidity, highly im-
paired quality of life, psychological distress and increased
healthcare costs due to treatment [10, 12]. With these
precedents, the individual patient’s situation becomes pref-
erence sensitive, requiring careful consideration and delib-
eration of many factors (e.g., diagnosis, prognosis, fears,
values, beliefs, ethics, hopes and previous experience) that
make decisions complex and highly preference sensitive.
Shared decision-making (SDM) is frequently advocated in
clinical practice as the fundamental component of all pa-
tient-provider interactions in regards to medical decisions
[13, 14] since it is based on the principles of patient-cen-
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tred care [15, 16]. It is particularly recommended for “pref-
erence-sensitive medical decisions” [17] and considered
essential for screening and treatment of prostate cancer
[18, 19]. With this approach, the decision depends to a
great extent on the patients’ informed preferences and on
their value of risks, benefits and harms of options [17].
These attributes are often integrated and tailored to the
patient’s circumstance by means of decision aids or oth-
er methods [20–23] that facilitate SDM [16]. However,
there is no single definition of SDM and no clear consen-
sus about how to conduct SDM in routine medical prac-
tice. Ongoing debate also indicates that the goal of SDM
is not yet clarified. Some view SDM as a partnership be-
tween patient and/or patient care-related parties (e.g., legal
guardian, relatives) and healthcare providers to equally
share decisions about healthcare choices [24–27]. For oth-
ers, SDM is a process to engage in decision-making [14,
28], or an approach to incorporate preference-sensitive el-
ements that facilitate decision-making [17].
SDM appeals greatly to policy makers and healthcare
providers because of its potential to reduce the overuse of
options with unclear benefits [29] while enhancing the use
of beneficial options [30] and reducing variations in prac-
tice [31]. We performed a systematic review to assess the
extent of SDM implementation in studies of interventions
aiming to facilitate SDM for men facing prostate cancer
screening and/or treatment decisions.
Methods
We developed a protocol before starting the review follow-
ing the principles for systematic reviews [32, 33], and we
report the methods in accordance with the PRISMA (Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses) guidelines (see table S1 in appendix 1 for the
PRISMA checklist) [34].
Inclusion and exclusion criteria
We focused on the extent to which the concept of SDM is
implemented in clinical practice. We assessed the report-
ed SDM interventions based on the SDM model (see sec-
tion “Assessment of SDM implementation”). We broad-
ly defined SDM interventions as the approaches, methods
or tools designed to facilitate, foster, or improve patient-
healthcare provider involvement in medical decision-mak-
ing, based on Charles et al. [35]. We included peer-re-
viewed and grey literature of studies reported in English
addressing (the effectiveness of) SDM interventions for
men facing decisions about prostate cancer screening and/
or treatment. Eligible studies were randomised controlled
trials (RCTs), quasi-RCTs (method of allocation not strict-
ly random), and cluster RCTs (1) comparing SDM inter-
ventions to one or more alternative interventions, and/or
usual care, (2) directed at patients and/or their care-related
parties and/or healthcare providers, and (3) conducted in
primary or specialised healthcare including general prac-
tices, community clinics, ambulatory care, hospitals and
private care services. Studies were included regardless of
the length of follow-up, publication year and country of
origin. We excluded studies conducted in non-clinical set-
tings and community studies in which discussions were not
intended or could not occur.
Search strategy and data sources
We designed and conducted a comprehensive search strat-
egy in Medline Ovid, Embase (Elsevier), CINHAL (EB-
SCOHost), The Cochrane Library (Wiley), PsychINFO
(EBSCOHost) and Scopus from their inception to March
2015. The search strategy was revised by an information
specialist and, included terminology compatible with SDM
(e.g., “patient participation” and “patient involvement”),
“shared decision making” and “prostate cancer” (see table
S2 in appendix 1). It was not restricted by publication date,
language, country or outcomes, and included a study de-
sign filter for the identification of RCTs in humans [36].
We also searched for grey literature using individual clin-
ical trial registers (clinicaltrials.gov and ISRCTN), the
WHO search portal (http://apps.who.int/trialsearch), and
the Ottawa Hospital Research Institute website
(http://www.ohri.ca). The records were accessed between
February and August 2016, and the trials registration num-
ber was additionally searched for by use of Medline and
PubMed. We also used Google Scholar and the system
for Information on Grey Literature in Europe (http://open-
grey.eu/). We identified additional studies by screening
the reference lists of included studies, relevant systematic
reviews and clinical guidelines, and by contacting (June
2015 to January 2017) the authors of potentially eligible
abstracts for which the full text could not be located.
Selection of studies
Two reviewers independently screened the titles and ab-
stracts of all citations, and examined the full text of po-
tentially eligible publications meeting the eligibility crite-
ria. Studies reported in more than one publication were
identified and treated as one unit. We resolved differences
through consensus or by involving an arbitrator.
Data collection and synthesis
One reviewer extracted data using standardised data col-
lection forms designed and developed a priori. A second
reviewer independently verified data extractions, resolving
differences by consensus or by involving an arbitrator. For
each study, we extracted information on the bibliograph-
ic details of studies (design, country, time of study con-
duct, funding sources), characteristics of study populations
and interventions, including the interventions’ attributes,
and the elements and key features of SDM implementa-
tion. Data from a single study reported across various pub-
lications were extracted as one unit. We obtained full-text
data from the authors of potentially eligible abstracts with-
out available full text. In this review, we performed a nar-
rative synthesis of the results, including a description of
the reported SDM interventions and their implementation
based on the SDM model. In a future report, we will in-
clude an analysis of the effectiveness of SDM interven-
tions.
Assessment of the extent of SDM implementation
We evaluated the extent of SDM implementation in accor-
dance with the essential characteristics of SDM proposed
by Charles et al. [35] (see table S3 in appendix 1). Of the
analytic stages of SDM, we considered deliberation to be
central and mandatory, and that it must be bi-direction-
al (i.e., active participation of both patient and healthcare
provider) for SDM to occur. Provision of information only,
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such as use of decision aids, cannot replace this active and
bi-directional participation, but such strategies in a “stand-
alone” format can facilitate SDM or become a component
of a multi-faceted intervention. To differentiate the variants
(e.g., two-way from one-way) in decision-making, we as-
sessed the intervention’s description and content, its deliv-
ery procedure and the mode of decisions to identify the el-
ements aiming to facilitate decision-making. We evaluated
whether:
1. The intervention aimed to facilitate or foster shared de-
cisions, for example by including elements of patient
activation, encouragement to talk or discuss, etc.
2. There was evidence of bi-directional interaction be-
tween patients and healthcare providers, such as
planned (telephone or face-to-face) consultations.
3. Implementation of decision-making was based on




c. make/implement a decision in consensus.
Ideally, this collection of behaviours occurs altogether
within a clinical encounter [35]. We anticipated, however,
that SDM definitions and goals would differ among studies
resulting in heterogeneous decision-making behaviours in
which SDM might not be achieved. We classified the in-
terventions as SDM (all criteria met), partial SDM (at least
deliberation met), unclear (unclear deliberation), and no
SDM (unidirectional interaction) by coding 3a, 3b and 3c
as one if the criteria was met, zero if the criteria was not
met, or unclear (?) if criteria details were not reported or
could not be verified. Table S4 (appendix 1) illustrates this
system.
We considered the following criteria as components of
SDM, since these were intended to encourage discussions
between patient and healthcare provider or implied a bi-
directional interaction between them: patient activation
strategies such as provision of information, patient
prompts, clinical encounters that occurred at or shortly be-
fore a healthcare appointment, coaching, interviews, or be-
fore filling out questionnaires.
Results
Identification of eligible studies
Our searches identified 15 398 records. After perusal of all
titles and abstracts, we excluded 15 128 records. We exam-
ined in detail the full text of 270 potentially relevant ar-
ticles. After excluding 220 articles, 36 RCTs reported in
50 publications met the inclusion criteria [37–86]. Figure 1
shows the flow of study identification and selection. Char-
acteristics of study, population and interventions of the 36
RCTs are summarised in supplementary table S5 (appen-
dix 1)
Study and population characteristics
The 36 RCTs were published from 1997 to 2015, and
44.4% (n = 16) were published between 2010 and 2015;
the median year of publication was 2008 (table 1). The
vast majority (77.8%) of RCTs were conducted in North
America (n = 28), and the remaining (22.2%) in Europe (n
= 7) and Australia (n = 1). Thirty-five parallel RCTs in-
cluded 18 484 randomised patients, and the cluster RCT
randomised 712 patients with 120 physicians and 55 wait-
ing areas. Twenty-three (63.9%) RCTs addressed decision-
making for prostate cancer screening. Of those, only five
(21.7%) defined screening as both testing for prostate-
specific antigen (PSA) and a digital rectal examination
(DRE); the other eighteen (78.3%) defined prostate cancer
screening as testing for PSA only. Twelve (33.4%) RCTs
addressed decision-making for prostate cancer treatment.
Nine (75%) of those provided a range of treatment options
of which surgery (n = 9) was the most commonly offered
choice, followed by radiotherapy (external beam radiation;
n = 7), watchful waiting (n = 6), brachytherapy (n = 6) and
hormone therapy (n = 4). One RCT addressed decision-
making for both screening and treatment of prostate can-
cer [86]. Thirty-two (88.9%) RCTs included patient-direct-
ed interventions, but four RCTs targeted both patients and
their significant other (e.g., relatives, spouses) [83, 84], or
patients and physicians [42, 45].
Patients were mainly recruited from primary care clinics
in 20 (55.6%) RCTs (table 2). In the other 16 (44.4%)
RCTs, patients were recruited from hospital-based (n = 5)
or cancer (n = 3) clinics, a specific population (n = 1), or
from multidisciplinary (combining at least two; n = 7) set-
tings. Thirty (83.4%) RCTs reported the targeted age of
participants. In 27 RCTs (75%), the minimum and max-
imum targeted age of men was 40 and 86 years, respec-
tively; one RCT (3%) targeted relatively young (younger
than typically recommended) men who were at least 18
years old [82]; and two RCTs (5.6%) did not use age as an
eligibility criterion for participants [68, 74]. Three RCTs
were not tied to a consultation [38, 48, 57], but the type
of participating healthcare providers was reported in 24
(66.7%) RCTs: 14 RCTs (38.8%) employed faculty, gen-
eral or internal medicine physicians, and nurse practition-
ers; and 10 RCTs (27.8%) employed physician special-
ists (urology, oncology, and/or radiation oncology). Eleven
(30.6%) RCTs reported the number of participating health-
care providers, which ranged from 2 [85] to 127 [54].
Seven RCTs (21.2%) reported the level of healthcare
providers’ training or experience, which ranged from post-
graduate practice to 40 years of experience, or board cer-
tified physicians. Thirty-four RCTs reported the funding
sources; these were non-profit governmental and private
institutions.
Attributes of decision-making interventions
The interventions varied widely in their delivery mode,
form, and content (table 3). SDM was considered within
the context of primary care in 55.5% (n = 20) of the RCTs,
multidisciplinary healthcare in 19.4% (n = 7), hospital care
in 14.0% (n = 5), specialised care in 8.3% (n = 3), and
from a population perspective in 2.8% (n = 1). The inter-
ventions were delivered on-site (n = 14), home (n = 9), on-
site or home (n = 9), home or on-site combined with other
settings (n = 3), and face-to-face or by telephone (n = 1).
Most interventions (n = 28) were delivered before consul-
tations, interviews or questionnaires, and a few were deliv-
ered during (n = 6) or after (n = 2) consultations or ques-
tionnaires. The interventions were self-administered in 20
(55.6%) RCTs, exclusively delivered by clinicians or re-
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search staff in 10 (27.8%) RCTs, and either delivered by
research staff or clinicians guided patients in 6 (16.7%)
RCTs.
A multifaceted strategy was used in nearly half (47.2%) of
the studies. Most interventions included material in paper-
based (n = 25) format although some included web-based
(n = 4), paper- and web-based (n = 2), or other format (e.g.,
interview, audiotape recording; n = 5). Healthcare litera-
cy levels were considered in the development or pilot test-
ing of the interventions in 19 RCTs (52.8%). Of these, one
RCT exclusively developed separate interventions for low
and high health literacy [51]; in two RCTs interventions
were designed for low health-literacy populations [46, 54];
one RCT considered the target population with a literacy
expert [58]; and one RCT used tailored literacy with a de-
cision navigator [72].
Elements and key features of SDM interventions
Twenty-five RCTs (70%) intended to assess SDM to some
degree (table 4). This intention was not clearly stated in
the other 11 RCTs (30%), although the interventions in-
cluded elements to facilitate or foster SDM in all but one
study. “Informed decision-making” was the most frequent-
ly (n = 21) used term, whereas only 9 (25%) RCTs used
the term SDM. The studies also referred to other terms and
measurements relevant to SDM including “weighing up
benefits and harms”, “risks”, “pros and cons of options”,
“patients’ values”, “preferences”, “promotion of engage-
ment”, “discussions of choices”, “activation” or “partici-
pation in decision-making appointments”, “decision role”
(e.g., active, passive), “patient autonomy”, “patient cen-
tredness”, “knowledge and beliefs”, and “decisional con-
flict”. The interventions varied widely in the operational
framework underlying their development, with the Ottawa
Decision Support Framework (n = 5) being the most com-
mon among the 23 RCTs that reported using a framework.
Other frameworks included the health belief model theory
(n = 2), the US Preventive Services Task Force (n = 2), the
Patient Centred (n = 2), and another twelve (n = 12) ap-
proaches.
The extent of SDM implementation varied widely among
studies (tables 2 and 4). Overall, 31 (86.1%) RCTs were
verified as showing bi-directional interactions between pa-
tient and healthcare provider. Of these, 28 (77.8%) RCTs
showed bi-directional interactions for information ex-
change and deliberation, but only 14 (50%) were verified
as having built consensus for decisions about screening or
treatment options. Of the 31 (86.1%) RCTs in which deci-
Figure 1: Identification and selection of studies.
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Table 1: Summary of the characteristics of 36 randomised controlled trials of decision-making interventions for prostate cancer.
Year of publication, mean (range) 2008 (1997–2015)
Studies included
35 parallel RCTs, randomised participants, n (range) 18 484 (60–3327)






United Kingdom 3 (8%)




PSA only 18 (50%)
PSA and DRE 5 (14%)
Treatment* 12 (33%)
Radical surgery 9 (100%)
Radiotherapy 7 (78%)
Brachytherapy 6 (67%)
Watchful waiting 6 (67%)
Hormone therapy 4 (44%)
No treatment 2 (22%)
Other† 7 (78%)
Screening and treatment: PSA only; surgery, radiotherapy, watchful waiting 1 (3%)
Age of study participants, range (years) 18–86
Number and specialty of participating healthcare providers‡, n (range) 2–127
Primary care providers: GPs or NPs 14 (58%)




Patients and partners or family members 2 (6%)
Patients and physicians 2 (6%)
Fostering of SDM
Intervention elements for fostering SDM 35 (97%)
Bi-directional interaction (physician ↔ patients) e.g., tied to consultations 31 (86%)
Key features of SDM
a) Information exchange (physician ↔ patients) 28 (78%)
b) Deliberation (physician ↔ patients) 28 (78%)
c) Implementation (physician ↔ patients) 14 (39%)
Intervention class¶ Screening Treatment Screening and treatment
1. SDM 8 (35%) 6 (50%)
2. Partial SDM 10 (43%) 3 (25%) 1 (100%)
3. Unclear 2 (9%) 1 (8%)
4. No SDM 3 (13%) 2 (17%)
DRE = digital rectal examination; GPs = general practitioners (faculty, general or internal medicine physicians); NPs = nurse practitioners; PSA = prostate-specific antigen; RCT
= randomised controlled trial; SDM = shared decision-making. Data are presented as n (%) unless otherwise stated. * Treatment options reported in nine of the twelve RCTs on
treatment. † Cryotherapy, pelvic lymph node dissection, transurethral resection, complementary, no preference, undecided, missing, “other”. ‡ Number of healthcare providers
reported in eleven RCTs, and the specialty of healthcare providers was reported in 24 RCTs. ¶ SDM key features [a-b-c] coded as: 1 = criteria met, 0 = criteria not met, or ? =
unclear (see table S4 in appendix 1).
sion-making involved at least two parties, 45.2% (screen-
ing, n = 8; treatment, n = 6) fulfilled the three key SDM
features: nine considered SDM within the context of pri-
mary care and five within the context of hospital and/or
specialised care. Another 45.2% (screening, n = 10; treat-
ment, n = 3; screening and treatment, n = 1) met the cri-
teria for partial SDM (verified deliberation); 3.2% (treat-
ment, n = 1) had all key SDM features difficult to verify
(unclear deliberation), and 6.4% (screening, n = 1; treat-
ment, n = 1) had the characteristics of no SDM. The other
five (13.9%) of the 36 included RCTs, showed unclear de-
liberation (screening, n = 1; treatment, n = 1) or no SDM
(screening, n = 2; treatment, n = 1).
Discussion
In this systematic review, we identified 36 RCTs of inter-
ventions aiming to facilitate SDM for screening and treat-
ment of prostate cancer in a variety of settings and popu-
lations. The majority of RCTs were from North America,
mainly the USA (n = 22). Most of the participating men
were 40 to 86 years old and more than half (55.6%) were
recruited from primary care. There was a wide variation in
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Participating HCP and special-
ty, n
Screening




n = 831 1) n = 840
2) n = 828
3) n = 828












n = 631 1) n = 630
2) n = 632
Not tied to a consultation - inter-
viewers, n = n.r.







n = 19 waiting ar-
eas, 113 patients,
36 physicians
1) n = 19 waiting ar-
eas, 246 patients, 41
physicians
2) n = 17 waiting ar-
eas, 353 patients, 43
physicians
Physicians in internal and family
medicine (4-40 years’ experience
since clinical training completed),
n = 120




n = 138 1) n = 134
2) n = 137
3) n = 134
Urology physicians or oncolo-
gists, n = n.r.
Landrey, 2013 [44] USA PSA UH GIMPs, 2 Patients
50–74
n = 145 1) n = 158 Internal medicine physicians, 44






n = 60 1) n = 70 Family physicians, 28





n = 244 1) n = 246 Primary care physician
Myers, 2011 [47] USA PSA PCs, 2 Patients
50–69
n = 156 1) n = 157 Family physicians (board-certified
practitioners), 22
Evans, 2010 [48] UK (South
Wales)





n = 129 1) n = 126
2) n = 127
3) n = 132
Not tied to a consultation
Stamatiou, 2008 [49] GRC PSA PC institutions Patients
50–86
n = 548 1) n = 587 Physicians, n = n.r.




n = 155 1) n = 153
2) n = 152
3) n = 151
Physicians, n = n.r.
Volk, 2008 [51] USA PSA HGP (low HL site),
1
UGP (high HL site),
1
Patients
40–70 if AA or
50–70 if not AA
n = 224 1) n = 226 Physicians, n = n.r.
Krist, 2007 [52, 53]
(Woolf, 2005)
USA PSA Suburban GP, 1 Patients
50–70
n = 226 1) n = 196
2) n = 75
Family physicians, 29 (13 faculty,
8 second-year residents, and 8
third-year residents)






n = 101 1) n = 101
2) n = 101
Nurse practitioners, 5;
internal medicine physicians, 109




faculty physicians, 13 (fully
trained)
Partin, 2006 [55, 56]
(Partin, 2004)
USA PSA VA GIMP, 4 Patients
≥50
n = 384 1) n = 384
2) n = 384
General internal medicine physi-
cians, n = n.r.
Watson, 2006 [57] UK (England
and Wales)
PSA GPs, 11 Patients
40–75
n = 980 1) n = 980 Not tied to a consultation






n = 121 1) n = 121 Family physicians, 4; internal
medicine physicians, 2; oncolo-
gist, 1
Gatellari, 2003 [59] AUS PSA Urban GPs, 13 Patients
40–70
n = 126 1) n = 122 Family physicians, 13
Frosch, 2003 [60, 61]
(Frosch, 2001)




n = 114 1) n = 112 Physicians, n = n.r.
Volk, 2003 [62, 63]
(Volk, 1999)
USA PSA UGP, 1 Patients
45–70
n = 80 1) n = 80 Primary care provider, n = n.r.






n = 122 1) n = 135 Physician or research physicians
(investigators), n = n.r.






n = 50 1) n = 50 Family physicians (first and sec-
ond year residents and academic
staff), n = n.r.
Wolf, 1998 [66, 67]
(Wolf, 1996)
USA PSA UGPs, 4 Patients
≥50
n = 103 1) n = 102 Primary care physicians, n = n.r.
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Participating HCP and special-
ty, n
Treatment





n = 73 1) n = 74 Urology physicians, radiation on-
cology physicians, medical oncol-











n = 266 1) n = 228 Physician consultants (urology or
oncology physician or other), n =
n.r.
Hacking, 2013 [72] UK (Scot-
land)
1, 5, 6, 7, 8 GH, 1 Patients
Age, n.r.†
n = 63 1) n = 60 Urology physicians or oncolo-
gists, n = n.r.
UMC, 1van Tol-Geerdink, 2013
[73]




n = 163 1) n = 77 Urology physicians, n = n.r.
UHs, 2Huang, 2014 [74–76]
(Auvinen, 2004; Auvi-
nen, 2001)










CAN 1, 2, 5, 6,
10, 12, 14
Ca clinic centres, 4 Patients
>40
n = 81 1) n = 75 Physicians, n = n.r.









n = 66 (95 CD
users)
1) n = 66 (25 non-CD
users)
Urology physicians, radiation on-
cology physicians, medical oncol-
ogy physicians, n = n.r.







n = 89 1) n = 93
2) n = 74
Physicians, n = n.r.







n = 214 1) n = 211 Fully trained radiation oncolo-
gists, n = 15








n = 162 1) n = 162 Urology physicians, n = n.r.
Feldman-Stewart, 2006
[84]





n = 152 1) n = 156 Physicians, n = n.r.





n = 30 1) n = 30 Urology physicians, 2
Screening and treatment




n = 275 1) n = 275 Physicians, n = n.r.
CAN = Canada; NLD = The Netherlands; SPN = Spain; FIN = Finland; GRC = Greece. LPC = localised prostate cancer; DRE = digital rectal examination; PSA = prostate-specific
antigen; AA = African American; n.r. = not reported; CD = CD-ROM-based decision aid. Settings: VA = Veterans’ affair; PC = primary care clinics/practices; GIMP = general in-
ternal medicine practice; AGIMP = academic general internal medicine practice; UH = university hospital; MGP = medical group practice; PP = physician partners; HMO = health
maintenance organisations; AMC = academic medical centre; Net = networks; UMC = university medical centre; UCaC = university cancer centre; AGP = academic general
practice; GH = general hospital; FMC = family medicine centre/clinic; IC = insurance company; GPs = general/family medicine practices/clinics; Prev = preventive; KP = Kaiser
Permanente; UGP = university-affiliated general practice; HGP = hospital-based general practice; HL = health literacy. Treatment options: 1 = radical surgery (prostatectomy
or “surgery”), 2 = cryotherapy (cryosurgery or cryoablation), 3 = lymphadenectomy (lymph node dissection), 4 = transurethral resection of the prostate, 5 = radiotherapy, 6 =
brachytherapy (combination of radiotherapy and surgery), 7 = hormone therapy (e.g., orchidectomy, LHRH agonist treatment, antiandrogen or oestrogen), 8 = watchful waiting or
active monitoring, 9 = complementary, 10 = no treatment, 11 = no treatment, preference, 12 = other (type not stated), 13 = undecided, 14 = missing. * Cluster RCT. † RCTs for
which no specific target age was used as eligibility criterion. ‡ RCTs for which age was not used as eligibility criterion.
the minimum age (range: 40–55) at which men were tar-
geted to be screened for prostate cancer with starting cut-
off ages at 40, 45, 50, 55 years, and 18 years in one study.
Primary care physicians or nurse practitioners participat-
ed in at least a third of the studies, whereas specialised
physicians participated in less than a third of the studies.
Most studies addressed decision-making for prostate can-
cer screening, with PSA being the most (78.3%) frequently
used method of diagnosis. The interventions differed wide-
ly in delivery mode, format and content.
Our approach for assessing the implementation of SDM in-
terventions was based on the criteria defined by Charles et
al. [24, 35]. The model distinguishes the roles and respon-
sibilities of the relationship between patient and health-
care provider for SDM compared with other models of de-
cision-making. The essential characteristic of SDM is the
bi-directional interaction between patient and healthcare
provider which places SDM in the middle between a pater-
nalistic and an informed-decision approach. Patients (and/
or related parties) and healthcare providers need to active-
ly adopt a set of behaviours in each of the analytic stages,
namely information exchange, deliberation and decision
implementation [35]. Our approach also supports delibera-
tion as the key feature to accomplish SDM in routine prac-
tice, in keeping with Elwyn et al. [87].
We found that different strategies are used to encourage
participation in decision-making, and interventions might
be considered to facilitate SDM, although they might not
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Lewis, 2015 [37] General medicine Single vs multi-
faceted




• On-site clinic or
home
Unclear/n.r. DVD DESI; n = 831 1) Invitation to partici-
pate in SMA appoint-
ment with provider and
other patients; n = 840
2) PSA DVD DESI +
SMA; n = 828
3) No additional inter-












interview (1 mo) (not
tied to consultation)
• Home
Yes Web-based DA; n =
631
1) Print-based DA; n =
630
2) UC; n = 632
Wilkes, 2013 [42] General medicine Multifaceted • Interactive web-
based
• Self-administered










tion + access to CDC
brochure; n = 19 wait-
ing areas, 113 pa-
tients, 36 physicians
1) Web-based physician
education + access to
CDC brochure; n = 19
waiting areas, 246 pa-
tients, 41 physicians
2) UC practice: CDC ed-
ucational brochures; n =










• on-site clinic or
home
Yes DA-Home CDC-
adapted booklet; n =
138
1) Fact sheet DA-Clinic
NCI booklet; n = 134
2) UC at home; n = 137
3) UC at clinic; n = 134
Landrey, 2013 [44] General medicine Single • Print-based flyer
• Self-administered




Yes Flyer with patient en-
couragement to talk
with providers; n =
145




General medicine Multifaceted vs
single




• Physicians or self-ad-
ministered
• 1 hour before con-
sultation
• On-site clinic (pri-
vate room)
Unclear/n.r. Video-based DA +
coaching session +
supplemental
brochure; n = 60
1) Educational video on
highway safety; n = 70




with training in public










tional pamphlet; n =
244
1) Attention control: tele-
phone tailored education




Myers, 2011 [47] General medicine Multifaceted • Face-to-face coun-
selling sessions
• Physicians






sion + generic note in
medical chart to
prompt discussions
with physician + infor-
mational brochure; n
= 156
1) SC: practice quality
assessment survey +
generic note in medical
chart to prompt discus-
sions + informational
brochure; n = 157
Evans, 2010 [48] General medicine Single • Web-based and text
(from web)
• Self-administered






• Home or other set-
tings
Unclear/n.r. Web-based DA Pros-
dex interactive pro-
gram; n = 129
1) Paper-based DA
Prosdex; n = 126
2) Control questionnaire;
n = 127












• During pre-test in-
terview and before
consultation
• On-site clinic or
home




1) UC: pre-test interview
with physician and
physician's advice; n =
587








net): home or work
Unclear/n.r. Web-based traditional
DA; n = 155
1) Web-based CDTM; n
= 153
2) Web-based TDA +
web-based CDTM (n =
152); n = 152
3) Web links to screen-
ing sites from ACS and
CDC; n = 151
Systematic review Swiss Med Wkly. 2018;148:w14584
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.















Volk, 2008 [51] General medicine Single • Video (interactive
edutainment), audio
booklet
• For subjects at the
low-literacy site: RA
read material
• For subjects at the
high-literacy sites: self-
administered
• RA were available to









storyline; n = 224
1) Audio booklet without
interactivity and enter-
tainment factors; n = 226
Krist, 2007 [52,
53] (Woolf, 2005)
General medicine Single • Internet link to web-
based or paper-based
• Self-administered
• Within 2 weeks of
consultation
• Home
Unclear/n.r. Web-based DA; n =
226
1) Pamphlet (paper ver-
sion of web-based) DA;
n = 196
2) UC with no pre-visit




Hospital Single • Print-based pam-




• On-site clinic (wait-
ing room)
Yes High-detail patient ed-
ucational pamphlet to
promote SDM; n =
101
1) Low-detail “Talk to
your doctor” Cue hand-
out; n = 101
2) Attention control: pic-
tured traditional food
pyramid; n = 101
Partin, 2006 [55,
56] (Partin, 2004)
General medicine Single • Video or print-based
pamphlet
• Self-administered
• Within 2 weeks be-
fore consultation
• Home
Yes Video “The PSA Deci-
sion: What YOU
Need to Know” by the
FIMDM; n = 384
1) Pamphlet developed
for study; n = 384
2) UC and whatever de-
cision-making support
provided in routine ap-
pointments; n = 384




• Not tied to consul-
tation, but delivered
at same time as
questionnaire
• Home
Yes Brief patient DA
leaflet + question-
naire; n = 980
1) Control questionnaire
only; n = 980












booklet + decision ed-
ucation session by
telephone; n = 121
1) SC: informational
booklet; n = 121
Gatellari, 2003
[59]






booklet; n = 126
1) Pamphlet by the Aus-















Unclear/n.r. Web-based DA; n =
114
1) Video DA; n = 112












Yes Educational video by
the FIMDM + accom-
panying brochure; n =
80
1) No intervention before
visit + brochure after 2
week follow-up assess-
ment; n = 80
Schapira, 2000
[64]




and RA present and
available to answer
questions
• 2 weeks before
consultation
• On site clinic






phlet; n = 122
1) Basic information
pamphlet; n = 135
Davison, 1999 [65] General medicine Multifaceted vs
single












and to participate de-
cision-making; n = 50
1) Attention control: dis-
cussion about general
issues; n = 50
Wolf, 1998 [66,
67] (Wolf, 1996)
General medicine Single • Written (information)




Yes Scripted overview of
PSA screening; n =
103
1) Brief control message
about PSA availability; n
= 102
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Single • Print-based booklet
• Self-administered





















Single • Computer (touch-
screen in clinic or com-




• On-site clinic or
home
Yes Tailored internet aid;
n = 266
1) Website links to es-
tablished information
about prostate cancer; n
= 228






Yes Coaching DA: prepar-
ing for tailored per-
sonal consultation
plan; n = 63
1) UC pathway with dis-
cussion of treatment op-


















+ discussion of treat-
ment choice with spe-
cialists; n = 163
1) UC with discussion of
treatment options with







• Verbal and written
(structured informa-
tion)









with urologist + struc-
tured information on
treatment options; n =
104



























ercises; n = 81
1) Computer DA inter-
view with well-structured
information and general
questions; n = 75
Taylor, 2010 [80] Multidisciplinary (hos-
pital and population-
based)




staff (at study research
offices)




after biopsy) but be-
fore (1 mo) follow-up
telephone interview
• On-site study office
or home
n.r. Information CD + in-
teractive decision
tools; n = 66
1) Information CD; n =
66




• Video DVD, booklet
and telephone calls
• Self-administered
and telephone calls by
nurse (trained in the
study intervention)
• 10 days to 2 weeks
before consultation
• Home
Yes TS: DVD + booklet +
4 telephone calls to
patients and primary
support person; n =
89
1) TD: DVD + booklet +
4 telephone calls to pa-
tients only; n = 93
2) UC: handout on stay-
ing healthy during treat-
ment; n = 74









encounter; n = 214
1) Consultation not au-
diotaped; n = 211
















ment to bring signifi-
cant others to ap-
pointment; n = 162
1) Generic information
videotape + written infor-
mation package + tele-
phone call four weeks
later + encouragement
to bring significant oth-




Specialised (Cancer) Single • Print-based booklet
• Self-administered












provided to patients; n =
156
Systematic review Swiss Med Wkly. 2018;148:w14584
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.

















Davison, 1997 [85] General medicine Multifaceted
(verbal and writ-
ten)
• Booklet, written and
verbal
• Research staff and
nurse gave interviews
in preparation for con-
sultation and helped








tation; n = 30
1) Written information
package; n = 30
Screening and treatment
Wilt, 2001 [86] General medicine Single • Print-based pamphlet
• Self-administered
• 7–10 days before
consultation
• Home
Yes Question and answer
printed sheets; n =
275
1) UC alone; n = 275
RA = Research Assistant; n.r. = not reported. DESI = DEcision Support Intervention; SMA = shared medical appointment; NCI = National Cancer Institute; CDC = Centers for
Disease Control and Prevention; ACS = American Cancer Society; TDA = traditional DA; CDTM = Chronic Disease Trajectory Model; FIMDM = Foundation for Informed Medical
Decision Making; TD = treatment direct; TS = treatment supplemented; CCE = Cancer Care and Epidemiology Unit from Cancer Research Institute; UC = usual care; SC =
standard care intervention.
be explicitly termed as such. Informed decision-making is
the most frequently used term in the literature and it could
be either a stand-alone strategy to facilitate SDM, or one
component of multi-faceted interventions. SDM could also
be measured as a process (e.g., recording consultations) or
can be conceptualised as an outcome.
The quality of implementation of SDM interventions var-
ied widely among studies. In most, the interventions were
consistent in providing information, and the majority (n
= 28) intended to involve deliberation to some degree. In
fact, interventions were mostly delivered before consulta-
tions, interviews, evaluations or questionnaires as an at-
tempt to empower patients. However, only 38.9% (n = 14)
met the key criteria for SDM as proposed by Charles et
al. [35]. Interestingly, half of the treatment studies, com-
pared with nearly 35% of the screening studies, achieved
the three key SDM features.
Given the prevalence of prostate cancer, that SDM is
guideline recommended and viewed as the fundamental
component of all interactions between patients and -health-
care providers, it is surprising to find only a small number
of studies on the effects of SDM for prostate cancer, espe-
cially treatment. However, nearly half (44.5%) of the in-
cluded studies were published from 2010 onwards, which
might indicate a growing area of research. In addition,
most (55.5%) studies considered decision-making within
the context of primary care by general practitioners, and
only a few evaluated decision-making in the context of
specialised care by urologists or oncologists. Moreover,
the study interventions were developed to target mostly
patients (88.9%), rarely involving the patients’ significant
others (e.g., family members, carers) despite recommenda-
tions that views and participation from others in decision-
making may lead to more efficient and effective healthcare
[29, 88].
Our review confirms an increase in the development of
SDM interventions for prostate cancer. It also confirms the
lack of both consensus on the definition of SDM and guid-
ance for SDM implementation in routine practice. Makoul
et al. [14] identified a range of 31 different SDM defini-
tions and, as noted in our review, their recommendations
for a single and more integrative concept of SDM are yet to
be followed. Future research should consider that this vari-
ability might make comparison across studies difficult, and
that consistent reporting of interventions and their compo-
nents could allow better estimation of SDM implementa-
tion. Involving others (e.g., patients’ carers or relatives) in
the process of decision-making might affect patient out-
comes and should be considered in further research. Nev-
ertheless, our results merit further evaluation of their im-
pact on patient outcomes.
Strengths and limitations
To our knowledge, this is the first systematic review about
SDM implementation for both screening and treatment for
prostate cancer. As such, this review focused on assessing
and describing the reported SDM interventions and their
implementation in clinical practice based on the SDM
model. Given the lack of a single SDM definition, we con-
sidered the diversity in the type of interventions that would
be compatible with SDM. Various reviews have focused on
decision aids. We used a broad definition of SDM inter-
ventions and did not limit our search strategy exclusively
to the term “shared decision-making” or “decision aids”.
We used a range of search terms relevant to decision-mak-
ing, including SDM and decision aids. We applied broad
inclusion criteria at the screening stage and full-text evalu-
ation, and included studies regardless of whether a specif-
ic decision was promoted. Our review also covered inter-
national literature with no restriction to countries or type
of healthcare provider. We included literature published in
English only, and academic databases were searched up
to March 2015. However, we made considerable efforts to
identify all relevant studies by comprehensively searching
both peer-reviewed and grey (accessed: February–August
2016) literature in twelve sources. We also contacted au-
thors (2015–2017) of abstracts for which full texts were
not available, increasing the chance of identifying more lit-
erature that is contemporary. Our work thus benefited from
the response of authors, which led to the identification of
more studies and thus more complete data were considered
for eligibility. Moreover, our method for evaluating the im-
plementation of SDM confirmed that research gaps in the
conceptualisation of SDM continue despite previous rec-
ommendations [14]. We used the SDM model by Charles
et al. [35] because it represents only one SDM concept, and
it is the most prominent [14] approach to viewing SDM
compared with other models of decision-making. Our re-
view thus presents the elements and key features of SDM
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Table 4: Elements and key features of decision-making interventions for prostate cancer screening and treatment.














































































General medicine Unclear/n.r. No Yes Yes Yes Yes Unclear 2,
[1-1-?]









































































Hospital Yes No Yes Yes Yes Yes Unclear 2,
[1-1-?]
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Yes Yes Yes Yes Yes Yes Yes 1,
[1-1-1]












General medicine Yes Yes Yes Yes Yes Yes Yes 1,
[1-1-1]
Screening and treatment
Wilt, 2001 [86] General medicine Unclear/n.r. Yes Yes Yes Yes Yes Unclear 2,
[1-1-?]
n.r. = not reported. General medicine = general, internal, family and/or community practice clinics, preventive medicine, Veterans’ affair or primary practice clinics. Class: 1 =
SDM, 2 = partial SDM, 3 = unclear deliberation, 4 = no SDM: no deliberation. Each SDM key feature [a-b-c] was coded as 1 = criteria met, 0 = criteria not met, or unclear (?) =
judgement could not be made owing to unclear or lack of reporting (see table S4 in appendix 1).
interventions and provides an overview of the extent of
SDM implementation for prostate cancer.
Our review was limited by the quality of reporting of inter-
vention details, which made the verification of SDM cri-
teria difficult at times. Thus we cannot exclude the possi-
bility that we underestimated SDM implementation. Many
studies were published within the last decade, but the use
of frameworks was lacking in nearly a third of them.
Conclusions
There is a significant variation in the components of SDM
interventions for prostate cancer screening and treatment.
Only 39% of the studies contained the SDM intervention
components suggested in the SDM model, and interven-
tions were implemented mostly within the context of pri-
mary care. These results merit further evaluation on patient
outcomes. There might be strong ethical, medical and in-
terpersonal reasons to recommend SDM. However, to date
there seems to be uncertainty about the SDM concept, in-
tervention content, and how to implement SDM in prac-
tice. A standardised SDM definition and guidance for
SDM implementation in practice that is feasible for several
clinical settings are needed.
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Table S1. PRISMA checklist. 
Section/topic  # Checklist item  Reported on page #  
TITLE  
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT  
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
1 
INTRODUCTION  
Rationale  3 Describe the rationale for the review in the context of what is already known.  1-2 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
2 
METHODS  
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
2 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow‐up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
2 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
2 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  




Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta‐analysis).  
2 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
2 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
2 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
na 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  2 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta‐analysis.  
2-3 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
na 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre‐specified.  
na 
RESULTS 
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions 
at each stage, ideally with a flow diagram.  
3 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
3 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  na 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
3-5 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  na 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  na 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  na 
  
DISCUSSION 
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
5 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
11 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  11-12 
FUNDING 
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 
the systematic review.  
No external 
funding 
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097. doi:10.1371/journal.pmed1000097  














Table S2. Search strategy for OVID Medline. 
Item Searches 
1 exp Decision Making/ or Decision Making, Organizational/ or Decision Trees/ or Decision Making/ or Decision Support Techniques/ or Decision 
Support Systems, Clinical/ or Decision Making, Computer-Assisted/ or exp Computer-Assisted Instruction/ or exp Patient Participation/ or exp 
Professional-Patient Relations/ or exp "Attitude of Health Personnel"/ or Counseling/ or exp Health Communication/ 
2 exp Informed Consent/ 
3 (choice behavior or decision making or shared decision making).mp,tw. 
4 (informed adj3 (consent or choice* or decision*)).mp,tw. 
5 ((decision* or decid*) adj4 (support* or aid* or tool* or instrument* or technolog* or technique* or system* or program* or algorithm* or process* or 
method* or intervention* or material*)).mp,tw. 
6 (decision adj3 (board* or guide* or counseling)).mp,tw. 
7 (computer* adj4 decision making).mp. 
8 (patient adj3 (participation or involvement or cent#d care)).mp,tw. 
9 ((risk communication or risk assessment or risk information) adj4 (tool* or method*)).mp,tw. 
10 interact* health communication*.mp,tw. 
11 (interact* adj (internet or online or graphic* or booklet*)).mp,tw. 
12 (interact* adj4 tool*).mp,tw. 
13 ((interact* or evidence based) adj3 (risk information or risk communication or risk presentation or risk graphic*)).mp,tw. 
14 adaptive conjoint analys#s.mp,tw. 
15 or/1-14 
16 (Prostat* adj3 (Neoplasm* or Cancer or tumo?r* or carcinoma)).mp,tw. 
17 exp Prostatic Neoplasms/ 
18 16 or 17 
19 15 and 18 
20 (letter or letter$ or editorial or historical article or anecdote or commentary or note or case report$ or case study).pt,sh. 
21 (animals not humans).sh. 
22 20 or 21 
23 19 not 22 
24 exp Randomized Controlled Trial/ or exp clinical trial/ 
25 randomized controlled trial.pt. 
  
26 randomized controlled trial.sh. 
27 controlled clinical trial.pt. 
28 random allocation.sh. 
29 double blind method.sh. 
30 single blind method.sh. 
31 or/24-30 
32 31 not 22 
33 exp clinical trial/ or exp Clinical Trials as Topic/ 
34 clinical trial.pt. 
35 ((singl$ or doubl$ or trebl$ or trpl$) adj25 (blind$ or mask$)).ti,ab. 
36 (clin$ adj25 trial$).ti,ab. 
37 (random$ or placebo$).ti,ab. 
38 (PLACEBO or RESEARCH DESIGN).sh. 
39 or/33-38 
40 39 not 22 
41 40 not 32 
42 exp EVALUATION STUDIES/ 
43 (comparative study or follow up studies or prospective studies).sh. 
44 (control$ or prospectiv$ or volunteer$).ti,ab. 
45 or/42-44 
46 45 not 22 
47 46 not (32 or 41) 




Table S3. Models of shared decision-making. 




Active: transfers selected 
information to patient; makes 
decisions about the therapy s/he 
considers best for the patient without 
obtaining personal information or 
involving the patient in decision-
making process. 
Active: shares information and therapy 
options, their benefits and harms with patient; 
discusses preferences and values with 
patient; recommends therapy alternatives; 
decides on the choice of therapy in consensus 
with the patient. 
Passive: transfers information and 
treatment options with benefits and 
harms to patient; withholds 
recommendations; makes no decisions. 
Active: patient’s preferences are 
transferred to HCP who has the 
knowledge to identify the treatment 
options most desirable from patient’ 
perspective and recommends such to 
the patient. 
Patient 
Passive: accepts professional 
authority and agrees to therapy 
proposed by professional. 
Active: shares information and knowledge; 
receives information; makes own judgement 
about options, harms and benefits; discusses 
values and preferences with HCP; decides on 
the choice of therapy in consensus with HCP. 
Active: receives information; makes 
own judgement on options, based on 
harms, benefits, values and 
preferences; chooses freely between 
options without HCP intervention; 
decides on therapy alone. 
Active: receives all information about 
the treatment and accepts or rejects it 
according to his/her expectations. 
 
 Requires the sharing of treatment preferences 
and decisions by both HCP and patients 
Preferences of the HCP are excluded Relies on the HCP determining patient 
preferences and including these in the 
decision. HCP may not accurately 
gauge patients’ preferences and thus 
patients’ perspective may not be 
involved in the decision 
Process flow 
Interaction Uni-directional: Bi-directional: Uni-directional: Uni-directional: 
Information-exchange   HCP → patient HCP  ↔ patient HCP → patient  HCP → patient 
type of information medical, legal requirement medical and personal, anything relevant for 
decision making 
medical, anything relevant and enough 
to enable patient to make a treatment 
decision 
 
Deliberation at least one HCP HCP and patient +/- patient care-related 
parties (significant others, legal guardian, 
relatives and/or caregivers or other clinicians)  
patient (+/- patient care-related parties: 
significant others, legal guardian, 





HCP HCP and patient patient HCP 
Adapted from Charles et. al. [24, 35].  
  
Table S4. Method for assessing the key features of SDM implementation. 
Extent of SDM a. information exchange (physician ↔ patients) 
b. deliberation 
(physician ↔ patients) 
c. implementation 
(physician ↔ patients) Classification 
1. SDM 1 1 1 [1-1-1] 
2. Partial SDM 
 
0 1 1 [0-1-1] 
1 1 0 [1-1-0] 
? 1 1 [?-1-1] 
1 1 ? [1-1-?] 
3. Unclear deliberation 
 
? ? ? [?-?-?] 
? ? 1 [?-?-1] 
1 ? ? [1-?-?] 
1 ? 1 [1-?-1] 
4. No-SDM: no deliberation 
No-SDM: unidirectional 0 0 0 [0-0-0] 
No-SDM: isolated information 1 0 0 [1-0-0] 
No-SDM: no deliberation 1 0 1 [1-0-1] 
No-SDM: isolated decision 0 0 1 [0-0-1] 
Key features based on Charles et al [24, 35]. 



















Inclusion criteria  Exclusion criteria  Intervention arm  Control arm  Operational 
framework Intervention & randomised 
patients, N 
Comparator & randomised 
patients, N 
SCREENING 
Lewis, 2015 [37]  USA 
 
RCT, parallel 
Feb 2011 to Dec 
2012 (intervention) 
Funding: non‐profit 
Primary care 
practices, 7 
Primary care 
academic general 
internal medicine 
practice, 1 
Men 50 to 75 years old, 
selected from the pool of 
eligible patients in the 
electronic medical records, 
without diagnosis of prostate 
cancer who had not had a PSA 
test in the past 10 months and 
who had not seen their 
primary care physician in the 
last 3 months 
n.r.  1) DESI group: 31 min PSA DVD 
DESI (decision Support 
Interventions) (developed by the 
Informed Medical Decisions 
Foundation); N=831 
1) SMA group: invitation to 
participate in a shared (group) 
medical appointment (SMA) to 
watch and discuss the PSA 
DVD DESI with a mid‐level 
healthcare provider and other 
patients; N=840 
2) DESI + SMA group: 31 min 
PSA DVD DESI + invitation to 
participate in a SMA; N=828 
3) No additional intervention 
material; N=828 
Unclear/n.r. 
Tomko, 2015 [38‐
41]  
(Starosta, 2015; 
Tomko, 2015; 
Taylor, 2013) 
USA 
 
RCT, parallel 
Oct 2007 to Jan 
2010 (recruitment) 
Funding: non‐profit 
University hospital, 1 
Hospital centre, 1 
Medstar physician 
partners, 1 
Men 45 to 70 years old, no 
prior history of prostate 
cancer, English speaking, with 
ability to provide informed 
consent, independent living, 
having had an outpatient visit 
in the last 24 months 
Men with history of prostate 
cancer, nursing home 
residents 
1) 8th grade reading level web‐
based DA with six informational 
sections, six video testimonials, 
and a values clarification tool; 
N=631 
1) 8th grade reading level 
print‐based DA with six 
informational sections, six 
video testimonials, and a 
values clarification tool; N=630 
2) Usual care; N=632 
Ottawa Decision 
Support 
Framework 
(ODSF)  
Wilkes, 2013 [42]  USA 
 
RCT, cluster 
May 2007 to Dec 
2008 
Funding: non‐profit 
Primary care 
networks academic‐
medical‐centre 
affiliated, 2 
Staff model health 
maintenance 
organisations, 2 
Medical group 
practice network, 1 
Men 55 to 65 years old, 
patients with no serious 
comorbidity (including any 
known cancer) and English 
speakers; physicians 
consented to participate in 
educational activities and to 
help recruit patients 
n.r.  1) MD‐Ed+A: 30‐min interactive 
web‐based educational program + 
30‐min web‐based patient 
activation + access to CDC 
brochure in waiting area; 19 
waiting areas, 113 patients, 36 
physicians 
1) MD‐Ed: 30‐min interactive 
web‐based educational 
program + access to CDC 
brochure in waiting area (19 
waiting areas; 41 physicians 
with 246 patients); 19 waiting 
areas, 246 patients, 41 
physicians 
2) Usual care practice: CDC 
educational brochures on 
prostate cancer in waiting 
areas (17 waiting areas; 43 
physicians with 353 patients); 
17 waiting areas, 353 patients, 
43 physicians 
Unclear/n.r. 
  
Williams, 2013 
[43] 
USA 
 
RCT, parallel 
Period, n.r. 
Funding: non‐profit 
University medical 
centre, 1 
University cancer 
centre, 1 
Men 40 to 70 years old, who 
had pre‐registered for 
screening at least 5 days in 
advance, had no history of 
prostate cancer and English‐
speakers 
Walk‐in patients  1) 20‐min 8th‐grade reading level 
DA‐Home booklet CDC‐adapted 
(mailed 5–10 days before the 
scheduled screening date), 24‐
page colour, titled "prostate cancer 
Screening: Making an Informed 
Decision"; N=138 
1) 5‐min, 3‐page fact sheet DA‐
Clinic booklet NCI (National 
Cancer Institute) (distributed 
at the screening appointment), 
titled "Questions and Answers 
About the Prostate Specific 
Antigen Test’’; N=134 
2) Usual care at home 
(information mailed to 
participants’ homes 5–10 days 
before screening date; 
contained little information 
about the prostate, treatment 
options, and had no values 
clarification tool); N=137 
3) Usual care at clinic 
(information was distributed 
at the screening appointment; 
contained little information 
about the prostate, treatment 
options, and had no values 
clarification tool); N=134 
Unclear/n.r. 
Landrey, 2013 
[44] 
USA 
 
RCT, parallel 
Oct 2009 to Aug 
2010 
Funding: non‐profit 
General internal 
medicine practices ‐ 
University‐Hospital 
affiliated, 2 
Men 50 to 74 years old, 
patients scheduled to have an 
annual health maintenance 
exam between October 2009 
and August 2010 
Men with PSA test within the 
past 12 months, had a history 
of prostate cancer, or any 
other diagnosis of cancer, 
terminal illness or dementia 
1) Flyer (mailed), 4th grade level 
(about the PSA test, prostate 
cancer, risks and benefits of 
screening) with patient 
encouragement to talk with their 
providers (about whether a PSA 
test was appropriate for them); 
N=145 
1) Usual care with no flyer; 
N=158 
Patient‐Centred 
Approach 
Sheridan, 2012 
[45] 
USA 
 
RCT, parallel 
Mar 2005 to Apr 
2006 
Funding: non‐profit 
Academic practice, 2 
Community practice, 
2  
Men 40 to 80 years old, with 
no prior history of prostate 
cancer, seen in the practice for 
at least 1 year; physicians also 
were invited and agreed to 
participate 
Men presenting for an acute 
medical visit, evidence of 
serious medical illness (e.g. 
Intensive care hospitalization 
within the last 6 months, 
more than 2 hospitalizations 
in the last 6 months) 
1) 12‐min video‐based DA + 8‐min 
coaching session + supplemental 
brochure; N=60 
1) Educational video on 
highway safety; N=70 
Shared 
Participation 
Approach to 
Decision‐Making 
Lepore, 2012 [46]  USA 
 
RCT, parallel 
Period, n.r. 
Funding: non‐profit 
Insurance company 
for beneficiaries 
healthcare workers' 
union, 1 
Men 45 to 70 years old, of 
Black African descent, 
accessible by telephone, have 
a primary care physician 
Men with prostate cancer test 
in the past 12 months before 
enrollment and who had a 
history of prostate cancer 
1) 2(max.)‐telephone tailored 
education sessions (initial call: 20‐
min; follow‐up call: 5‐min) within 1 
month (median: 1 week) about 
prostate cancer testing with key 
elements (rapport building, values 
clarification and importance of 
talking with a physician) + low 
1) Attention control: 2(max.)‐
telephone tailored education 
sessions (initial call: 20‐min; 
follow‐up call: 5‐min) within 1 
month (median: 1 week) about 
fruit and vegetable 
consumption + educational 
pamphlet (mailed); N=246 
Ottawa Decision 
Support 
Framework 
(ODSF)  
  
literacy educational pamphlet 
(mailed), titled "Prostate Cancer: 
Your Life‐You Decide" about 
advantages and disadvantages of 
prostate cancer testing, prostate 
cancer risk factors and prostate 
cancer tests, potential risks and 
benefits of testing; N=244 
Myers, 2011 [47]  USA 
 
RCT, parallel 
Between 2003 and 
2007 
Funding: non‐profit 
Primary care 
practice, 2 
Men 50 to 69 years old, with 
no history of prostate cancer 
or benign prostatic 
hyperplasia, who had no PSA 
test in past 11 months 
n.r.  1) Enhanced intervention: 28‐min 
(mean) structured decision 
counselling session (about prostate 
cancer screening) + generic note in 
medical chart to prompt physician 
to discuss prostate cancer + 12‐
page informational brochure (on 
prostate cancer and screening); 
N=156 
1) Standard intervention: 
practice quality assessment 
survey (to match face time of 
intervention group) + generic 
note in chart to prompt 
discussion of prostate cancer 
screening + 12‐page 
informational brochure (on 
prostate cancer and 
screening); N=157 
Decision 
Counselling 
Theory (as 
mediated 
decision support 
to inform SDM) 
Evans, 2010 [48]  UK (South Wales) 
 
RCT, parallel 
Period, n.r. 
Funding: non‐profit 
General practices 
from nine local 
health board areas, 
25 
Men 50 to 75 years old, who 
had not had a PSA test or 
prostate cancer, and able to 
use a computer and read 
English 
Men participants who could 
not read English, those whose 
general practice records 
indicated that they had 
previously had prostate 
cancer or a PSA test 
1) Web‐based DA, Prosdex 
interactive program (online 
program on options’ outcomes, 
clinical problem, outcome 
probabilities, explicit values 
clarification, others’ opinion, 
guidance); N=129 
1) Paper version of Prosdex 
text (online DA on options’ 
outcomes, clinical problem, 
outcome probabilities, explicit 
values clarification, others’ 
opinion, guidance (interactive 
computer program; summary); 
N=126 
2) Control questionnaire; 
N=127 
3) Control no questionnaire 
(received nothing); N=132 
Informed 
Decision Making 
Measure 
Stamatiou, 2008 
[49] 
GRC 
 
RCT, parallel 
Apr 2004 to 2006 
Funding: n.r. 
Primary care 
institutions 
Men 50 to 86 years old, who 
had a scheduled primary care 
appointment for various 
medical conditions except 
prostate‐related conditions 
Appointment for prostate‐
related conditions 
1) Pre‐test interview with the 
physician + additional printed 
written information in the form of 
an 554 words double‐sided a3 
sheet illustrated educational leaflet 
"prostate cancer screening"; 
N=548 
1) Usual care: pre‐test 
interview with the physician 
with physician's advice during 
interview in the examination 
room; N=587 
Patient‐Centred 
Approach 
Frosch, 2008 [50]  USA 
 
RCT, parallel 
Mar 2005 to May 
2006 (recruitment) 
Funding: non‐profit 
Preventive medicine 
clinic (Kaiser 
Permanente), 1 
Men older than 50 years, who 
made an appointment at the 
clinic, and who had broadband 
Internet access at home or at 
work, and with informed 
consent 
n.r.  1) Web‐based traditional DA (TDA) 
with information on the clinical 
problem, outcome options and 
probabilities, others’ opinions; 
N=155 
1) Web‐based Chronic Disease 
Trajectory Model (CDTM) with 
information on the clinical 
problem, outcome options and 
probabilities, others’ opinions, 
and with explicit values 
clarification (utilities for 
Unclear/n.r. 
  
outcomes associated with 
prostate cancer); N=153 
2) Combined TDA and CDTM 
(n=151) with explicit values 
clarification (utilities for 
outcomes associated with 
prostate cancer); N=152 
3) Links to public ACS and CDC 
prostate cancer screening 
websites; N=151 
Volk, 2008 [51]  USA 
 
RCT, parallel 
Jan 2004 to Feb 
2006 (data 
collection) 
Funding: non‐profit 
General medicine 
clinic from publicly 
funded hospital (low 
health literacy site), 1 
University affiliated 
family medicine clinic 
(high health literacy 
site), 1 
Men 40 to 70 years old if 
African‐American, or aged 50 
to 70 years if not African‐
American, who visited clinic 
for non‐acute care, with no 
history of prostate cancer 
n.r.  1) Interactive and entertainment 
multimedia DA (edutainment DA 
with tailored computerized 
program with information options’ 
outcomes, clinical problem, explicit 
values clarification, others’ 
opinion, guidance); N=224 
1) Audio booklet without 
interactivity and 
entertainment factors; N=226 
Edutainment 
Decision Aid 
Model (EDAM) 
Krist, 2007 [52, 
53] 
(Woolf, 2005) 
USA 
 
RCT, parallel 
Jun 2002 to Jun 
2004 
Funding: non‐profit 
Suburban family 
practice centre, 1 
Men 50 to 70 years old with a 
scheduled health maintenance 
examination 
Men with history of prostate 
cancer, lacked internet access, 
planned on having blood work 
before their visit, were 
enrolled in another prostate 
cancer investigation, or had 
already been enrolled in the 
study 
1) Web‐based DA (about options’ 
outcomes, clinical problem, 
outcome probability); N=226 
1) 4‐page pamphlet (mailed) 
paper version of web‐based 
DA (with same information as 
web‐based da); N=196 
2) usual care with no pre‐visit 
educational material; N=75 
US Preventive 
Services Task 
Force (USPSTF)  
Kripalani, 2007 
[54] 
USA 
 
RCT, parallel 
Jun‐Jul 2003 
(enrollment) 
Funding: non‐profit 
Teaching hospital, 1  Men 45 to 70 years old, 
waiting for primary care 
appointment 
Men enrolled previously, had 
history of prostate cancer as 
determined by a focused 
review of the patient’s 
electronic medical record, in 
police custody, arrived ill on a 
stretcher, not scheduled to 
see a primary care provider 
(i.e. Nurse‐only visits, medical 
student appointments, and 
refill pickups were excluded) 
for a full visit, not fluent in 
English on face‐to‐face 
screening, corrected visual 
acuity worse than 20/60 as 
assessed by a pocket vision 
screening card 
1) 6th grade level high‐detail two‐
sided patient educational 
pamphlet to promote SDM; N=101 
1) 5th grade level low‐detail 
one‐sided ‘talk to your doctor” 
cue handout; N=101 
2) Pictured traditional food 
pyramid (attention control); 
N=101 
Unclear/nr 
  
Partin, 2006 [55, 
56] 
(Partin, 2004) 
USA 
 
RCT, parallel 
Apr‐Jun 2001 
(recruitment) 
Funding: non‐profit 
General internal 
medicine Veterans' 
Affair Medical clinic, 
4 
Men veterans of at least 50 
years of age, with no prostate 
cancer, scheduled for general 
internal medicine 
appointment at one of the 
four participating centres 
between April and June 2001 
n.r.  1) 10th grade level 23‐min mailed 
video "The PSA Decision: What 
YOU Need to Know" (developed by 
FIMDM); N=384 
1) 6th grade level mailed 
pamphlet (developed for 
study); N=384 
2) Usual care and whatever 
decision‐making support 
provided in routine 
appointments; N=384 
Social Cognitive 
Theory 
Watson, 2006 [57] UK (England and 
Wales) 
 
RCT, parallel 
Jan‐Aug 2004 
(recruitment) 
Funding: n.r. 
General practices, 11  Men 40 to 75 years old, with 
no history of prostate cancer 
n.r.  1) Brief patient DA leaflet (‘PSA 
testing for prostate cancer—an 
information sheet for men 
considering a PSA test’; options’ 
outcomes, clinical problem, 
outcome probability) + 
questionnaire; N=980 
1) Control questionnaire only; 
N=980 
DA production 
conformed to 
accepted 
standards for the 
provision of 
patient 
information  
Myers, 2005 [58]  USA 
 
RCT, parallel 
Aug 1999 to Jul 2000 
Funding: non‐profit 
Community‐based 
primary care 
practice, 3 
Men older than 40 (final 
sample: 40 to 69) years, of 
African‐American origin, from 
the participating practices, 
with no history of prostate 
cancer or benign prostate 
hyperplasia, who had not 
undergone a prostate biopsy 
or prostate ultrasound, had 
visited one of the participating 
practices within two years 
prior to study initiation, and 
had contact information 
available at the practice and 
informed consent 
n.r.  1) Enhanced intervention: 
informational booklet (mailed) 
(about prostate cancer options’ 
outcomes) + decision education 
session (about clinical problem, 
explicit values clarification, 
guidance/coaching) by telephone 
(patients contacted by trained 
health educator by telephone 1 
month after booklet mailing; 
N=121 
1) Standard intervention: 
informational booklet (about 
prostate cancer clinical 
problem and options’ 
outcomes); N=121 
US Preventive 
Services Task 
Force (USPSTF)  
Gatellari, 2003 
[59] 
AUS 
 
RCT, parallel 
Period, n.r. 
Funding: non‐profit 
Urban general 
practices, 13 
Men 40 to 70 years old, 
sufficiently fluent in English, 
not diagnosed with prostate 
cancer, from 13 general 
practitioners (GPs) in urban 
Sydney 
n.r.  1) Evidence‐based booklet, 7.3‐
level Flesch–Kincaid, 32‐page, 
3085‐word (with essential content 
to inform decision making about 
PSA screening, in quantitative data 
form with maximised readability; 
includes a section for patients to 
write down the questions they 
might have for their doctors and 
another section suggesting 
patients to discuss or ask questions 
to their doctors); N=126 
1) Pamphlet, 11.2‐level 
Flesch–Kincaid, 968‐word, 
published by the Australian 
government (information to 
advise men of the agreed 
policy about PSA screening, in 
non‐numerical data form); 
N=122 
Unclear/n.r. 
Frosch, 2003 [60, 
61]  
(Frosch, 2001) 
USA 
 
RCT, parallel 
Preventive medicine 
clinic, 1 
Men older than 50 years, who 
made an appointment at the 
clinic, who had broadband 
n.r.  1) 47‐slide, 25‐30 min, web‐based 
DA (without pause) mirroring 
videotape DA content; N=114 
1) 23‐minute video DA (dialog 
about options’ outcomes, 
clinical problem, outcome 
Unclear/n.r. 
  
Period, n.r. 
Funding: non‐profit 
Internet access at home or at 
work and informed consent 
probability, others’ opinions; 
N=112 
Volk, 2003 [62, 
63] 
(Volk, 1999) 
USA 
 
RCT, parallel 
Feb‐Jun 1997 
(enrollment) 
Funding: non‐profit 
University family 
medicine clinic, 1 
Men 45 to 70 years old, with 
no history of prostate cancer 
and who presented for care at 
the participating centres, or 
patients with urinary 
incontinence or erectile 
dysfunction 
n.r.  1) 20‐minute educational 
videotape " the PSA decision: what 
you need to know" (developed by 
the foundation for informed 
medical decision making, Inc.) + 
accompanying brochure; N=80 
1) No intervention at baseline 
(before visit) + brochure after 
2 week follow‐up; N=80 
Shared Decision 
Making 
Approach 
Schapira, 2000 
[64] 
USA 
 
RCT, parallel 
Period, n.r. 
Funding: non‐profit 
Veterans' Affair 
Medical Center 
Outpatient Clinic, 1 
Men 50 to 80 years old with 
an outpatient (encounter) visit 
between 1990 to 1995 at the 
participating centre 
Men with history of prostate 
or other cancer, previous 
prostate ultrasound study or 
biopsy, cystoscopy, prior 
prostate surgery, active 
genitourinary symptoms, 
cognitive impairment (defined 
by a mini‐mental state 
examination score of 23 or 
less), an anticipated life 
expectancy of less than two 
years, or who were currently 
employed by the Veterans' 
Affair Medical Center 
1) 8‐page DA pamphlet with 
information about screening and 
treatment + educational (basic 
prostate cancer) information 
included in the comparator 5‐page 
pamphlet; N=122 
1) 5‐page written pamphlet 
with basic information about 
prostate cancer (no 
information on risks and 
benefits of screening); N=135 
Health Belief 
Model Theory 
Davison, 1999 
[65] 
CAN 
 
RCT, parallel 
Period, n.r. 
Funding: non‐profit 
Family medical 
teaching Centre, 1 
Men 50 to 79 years old, with a 
periodic health examination 
appointment with no previous 
history of prostate cancer or 
evidence of mental confusion, 
able to read, speak and write 
English; men previously 
screened for prostate cancer 
were also included 
n.r.  1) Verbal and written information 
(about prostate cancer screening 
controversies, pros and cons of 
having DER and/or PSA) with 
encouragement to discuss with 
family physician and to participate 
in making a screening decision to 
the extent patients were 
comfortable); N=50 
1) Attention control: 
discussion about general 
issues (prior to medical 
appointment and about the 
same length of time than 
intervention group); N=50 
Unclear/n.r. 
  
Wolf, 1998 [66, 
67] 
(Wolf, 1996) 
USA 
 
RCT, parallel 
Jun 1994 to Mar 
1995 (recruitment) 
Funding: non‐profit 
University family 
practices, 4 
Men of at least 50 years of 
age, English speakers visiting 
their primary care physicians 
for outpatient appointments, 
with no personal history of 
prostate cancer and who had 
not been screened with PSA, 
and with informed consent 
Men with prior PSA screening 
and personal history of 
prostate cancer 
1) Scripted overview of PSA 
screening; N=103 
1) Brief control message about 
PSA availability; N=102 
Health Belief 
Model Theory 
TREATMENT 
Chabrera, 2015 
[68] 
SPN 
 
RCT, parallel 
Jun 2011 to Jun 
2013 
Funding: non‐profit 
University hospital, 1 
Oncology institutes, 
2 
Men older than 45 years, 
newly diagnosed in the early 
stages of localized prostate 
cancer (T1Y2/N0/M0), not 
receiving therapeutic 
treatment for prostate cancer, 
and able to read and write in 
Spanish 
Men having a primary tumor 
type different from prostate 
cancer, having been 
diagnosed for any type of 
cognitive deterioration, 
psychiatric or addictive 
disorders that would preclude 
taking part in the process of 
shared decision making, and 
unwillingness to give 
informed consent to 
participate in the study; and 
patients with stage t1an0m0 
tumours, because their 
treatment consists of active 
follow‐up until signs of 
disease progression, and 
hence there is no real choice 
of treatment 
1) Printed booklet DA for localised 
prostate cancer with values' 
clarification exercises and with 
preparation material for 
consultation; N=73 
1) Standard information for 
localised prostate cancer; 
N=74 
Ottawa Decision 
Support 
Framework 
(ODSF)  
Berry, 2013 [69‐
71] 
(Berry, 2012; 
Bosco, 2012) 
USA 
 
RCT, parallel 
Mar 2007 to Nov 
2009 
Funding: non‐profit 
Veterans' Affair 
hospital, 3 
University cancer 
centre, 1 
Cancer centre 
institute, 2 
Men older than 40 years, with 
T1 or T2, histologically‐proven 
localised prostate cancer, 
were consulting with 
specialists who perceived that 
each participant was a 
candidate for at least 2 
treatment options, and had 
not begun therapy 
Men with advanced disease or 
those who had received prior 
treatment 
1) Tailored internet aid: baseline 
validated questionnaires with the 
P3P assessment component and 
research measures + P3P printed 
education and text and interactive 
web video coaching tailored to 
patients' personal profile (video on 
options’ outcomes, clinical 
problem, outcome probabilities, 
others’ opinion, guidance (list of 
questions to ask doctor and 
automated summary); N=266 
1) Website links to prostate 
cancer information: baseline 
validated questionnaires with 
the P3P assessment 
component and research 
measures + links to 
established information 
websites about prostate 
cancer; N=228 
Ottawa Decision 
Support 
Framework 
(ODSF)  
  
Hacking, 2013 
[72] 
UK (Scotland) 
 
RCT, parallel 
Jan 2009 to Aug 
2010 (eligibility 
assessment) 
Funding: non‐profit 
General hospital, 1  Men who had just received a 
diagnosis of localised or early 
stage primary prostate cancer, 
those who had a decision to 
make regarding cancer 
management and who were 
referred to a specialist urology 
consultant; age not used as 
inclusion criteria; final sample 
65.4 and 67.2 for intervention 
and control group respectively 
Men with any cognitive or 
sensory impairment, which 
impeded participation in the 
trial, and those who had 
already opted for active 
monitoring or to commence 
hormone treatment at 
diagnosis 
1) DA coaching ‐ decisional 
navigator by telephone or in 
person to guide patients in 
preparing for a consultation (by 
identifying and framing key 
questions and concerns regarding 
cancer management options) to 
generate a tailored personal 
consultation plan for the 
appointment; N=63 
1) Usual care pathway for 
prostate cancer patients 
meeting with a specialist 
consultant to discuss 
treatment options within a 
month of diagnosis; N=60 
Situation, 
choices, 
objectives, 
people, 
evaluation, and 
decisions 
checklist 
(scoped) 
van Tol‐Geerdink, 
2013 [73] 
NLD 
 
RCT, parallel 
Mar 2008 to Feb 
2011 
Funding: non‐profit 
University medical 
centre, 1 
General hospitals, 2 
Men with primary localized 
prostate cancer (T1–3an0m0), 
intending to be treated and 
eligible for both radiotherapy 
and radical prostatectomy; 
age not selected as inclusion 
criteria; final sample age: 64 
(SD5) years 
Men with contra‐indications 
for surgery (based on for 
example age or cardiovascular 
problems) or external 
radiotherapy (based on for 
example Crohn’s disease), 
mental or cognitive problems 
as assessed by the physician, 
inadequate knowledge of the 
Dutch language or a 
preference for active 
surveillance. We excluded 
active surveillance patients 
because our decision aid did 
not include risk information 
on this option. Brachytherapy 
was offered only to a selected 
group of patients. Exclusion 
criteria for brachytherapy 
were a small or large prostate 
volume (<20 ml or >50 ml), 
PSA > 15, Gleason >7 and/or 
severe urinary symptoms 
(requiring medication or, if 
available, IPSS > 12 and/or 
Qmax < 15 ml/s). 
1) DA consultation in semi‐
structured interview with 
researcher to provide information 
+ discussion of treatment choice 
with (their) specialists; N=163 
1) Usual care: discussion of 
treatment choice with (their) 
specialists; N=77 
Ottawa Decision 
Support 
Framework 
(ODSF)  
Huang, 2014 [74‐
76] 
(Auvinen, 2004; 
Auvinen, 2001) 
FIN 
 
RCT, parallel 
Period, n.r. 
Funding: non‐profit 
University hospitals, 
2 
General hospitals, 2 
Men with new histologically 
confirmed prostate cancer 
(between September 1993 
and November 1994), with the 
ability to complete the study 
questionnaire, as judged by 
the urologist in charge of 
treatment, with no exclusion 
Men with inability to 
participate because of 
dementia or strongly impaired 
general condition, and 
patients with stage t1an0m0 
tumours, because their 
treatment consists of active 
follow‐up until signs of 
1) Enhanced participation: 
extensive consultation with 
urologist where patient‐defined 
own role in treatment choice 
actively emphasised (with 
discussions about various aspects 
of available treatment options, 
including survival rate, adverse 
1) Standard treatment 
protocols; N=106 
Unclear/n.r. 
  
criteria based on age of the 
patient or extent of the 
disease; severe coronary heart 
disease for major surgery was 
not regarded as an exclusion 
criterion 
disease progression, and 
hence there is no real choice 
of treatment 
effects and cost, and the patient’s 
opinion about the aims of 
treatment and willingness to 
accept potential side‐effect) + oral 
and written structured information 
about treatment options; N=104 
Feldman‐Stewart, 
2012 [77‐79] 
(Feldman‐Stewart, 
2004; Feldman‐
Stewart, 2001) 
CAN 
 
RCT, parallel 
Period, n.r. 
Funding: non‐profit 
Cancer clinic centres, 
4 
Men older than 40 years, with 
newly diagnosed prostate 
cancer with low‐ or 
intermediate‐risk early‐stage 
disease (stage T1 or T2, 
prostate‐specific antigen <20 
and Gleason <8), visiting the 
cancer clinic for their first 
consultation and faced with 
making a treatment decision, 
understood English well‐
enough to complete the DA 
Men with a cognitive or 
emotional challenge that 
would preclude him from 
using the patient DA in a 
meaningful manner or that it 
would be potentially harmful 
or upsetting to him, in the 
opinion of the treating 
physician 
1) Computer DA and interview with 
well‐structured information with 
Value Clarification Exercises (Val 
Ex); N=81 
1) Computer DA and interview 
with well‐structured 
information with general 
questions (selection of 
attributes); N=75 
Differentiation 
and 
Consolidation 
Theory 
Taylor, 2010 [80]  USA 
 
RCT, parallel 
Sep 2002 to Nov 
2004 
Funding: non‐profit 
University hospital, 1 
Hospital centre, 1 
Local prostate cancer 
support groups and 
newsletters 
Men with newly diagnosed, 
early‐stage prostate cancer 
(T1‐T2N0M0; any Gleason 
score), English speakers, with 
absence of cognitive 
impairment, no prostate 
cancer history, treatment 
decision not yet made, and 
treatment choice not limited 
by comorbidities or age; no 
exclusion criteria based on 
age; final sample age: 64.6 
(SD9.4) years 
n.r.  1) 4hr information CD‐Room + 3 
interactive Decision Tools; N=66 
(95 CD users) 
1) Information only; N=66 (25 
non‐CD users) 
Unclear/n.r. 
Mishel, 2009 [81]  USA 
 
RCT, parallel 
Period, n.r. 
Funding: non‐profit 
Cancer centre, 2 
Community hospital, 
3 
Veterans' Affair 
Medical Center, 1 
Men with staging (t1a, b, c or 
T2a or b); Gleason score less 
than 10; PSA level less than 
20; at least 10 days before the 
treatment consultation 
appointment; no major 
cognitive impairment; ability 
to read; access to a telephone; 
no prior cancer history; and a 
primary support person 
designated by the patient who 
was willing to participate in 
the study 
Men with advanced disease 
beyond stage t2b 
1) Treatment supplemented: DVD 
+ Booklet + 4 Telephone calls by 
(trained) nurse to both patients 
and patient primary supporting 
person (e.g. Spouse); N=89 
1) Treatment direct: DVD + 
Booklet + 4 Telephone calls by 
(trained) nurse to patients 
only; N=93 
2) control ‐ usual care (?): 
handout on staying healthy 
during treatment; N=74 
Uncertainty 
Illness Theory  
  
Hack, 2007 [82]  CAN 
 
RCT, parallel 
Feb‐Dec 2001 
Funding: non‐profit 
Tertiary oncology 
clinic treatment 
facilities, 4 
Men older than 18 years, 
newly diagnosed with prostate 
cancer, who were presenting 
to a tertiary oncology clinic for 
their primary treatment 
consultation, discerned to be 
free of any cognitive 
impairment that would disable 
them from providing informed 
consent 
n.r.  1) Audiotape: a) audio recording of 
clinical encounter audio‐taped and 
given to patient (t2); b) audio 
recording of clinical encounter: 
audio‐taped and offered patient 
the choice of receiving audiotape 
or not (t3); N=214 
1) No audiotape: a) audio 
recording of clinical 
encounter: audio‐taped and 
not given to patient (t1); b) 
standard care: consultation 
not audio‐taped; N=211 
Unclear/n.r. 
Davison, 2007 
[83] 
CAN 
 
RCT, parallel 
Period, n.r. 
Funding: non‐profit 
Prostate education 
and research centre 
within a general 
hospital, 1 
Men newly diagnosed with 
localised prostate cancer, with 
biopsy‐proven early‐stage 
prostate cancer, who were 
aware of their diagnosis, had 
their initial urologic treatment 
consultation, not scheduled 
for definitive treatment within 
the next 4 weeks, and able to 
read and write English; age 
not selected as inclusion 
criteria; final sample 62.4 
years (SD6.9); partners were 
included in the sessions if they 
accompanied the patient 
n.r.  1) Individualized information 
printout based on information 
preferences and patient’s disease 
characteristics + Written 
information package + Telephone 
by Research Nurse approximately 4 
weeks later + Encouragement to 
bring their significant others to the 
appointment who were also 
included in the sessions; N=162 
1) Generic information 
videotape + written 
information package + 
telephone by research nurse 
approximately 4 weeks later + 
encouragement to bring their 
significant others to the 
appointment who were also 
included in the sessions; 
N=162 
The Decision 
Support 
Framework (by 
O'Connor) 
Feldman‐Stewart, 
2006 [84] 
CAN 
 
RCT, parallel 
Period, n.r. 
Funding: non‐profit 
Ambulatory cancer 
centres, 3 
Men with stage 1 or 2 prostate 
cancer, PSA <20, Gleason 
score <8, emotionally and 
cognitively capable of 
completing the task (judged by 
the oncologist), and judged by 
themselves as being able to 
read English. Family members 
were eligible if they were 
older than 18 years 
n.r.  1) 8th grade‐Flesch‐Kincaid CCE 
information booklet, developed by 
authors at cancer centre and 
designed for patients with low or 
intermediate risk disease; N=152 
1) Standard information 
booklet routinely provided to 
patients, developed by 
AstraZeneca; N=156 
Unclear/n.r. 
Davison, 1997 
[85] 
CAN 
 
RCT, parallel 
Period, n.r. 
Funding: non‐profit 
Community clinic 
with practicing 
urologists, 1 
Men newly diagnosed with 
prostate cancer, having been 
told their diagnosis: not having 
had their initial treatment 
consultation, able to read, 
speak, and write English, and 
with no evidence of mental 
confusion; age not selected as 
inclusion criteria; final sample 
age range: 41‐81 
n.r.  1) Empowerment intervention 
(interview preparing for 
consultation): Written information 
package (five brochures about 
prostate cancer) + Questions List 
to ask physicians (with discussion 
with investigator with additional 
questions prompted from 
discussions added to list) + Blank 
audiotape (to record consultation) 
1) Written information 
package (five brochures about 
prostate cancer) + package 
content shown + 
recommendation to read the 
information before or after the 
initial treatment consultation 
with their physician + social 
component in the interview; 
N=30 
Self‐Efficacy 
Theory within 
The 
Empowerment 
Model (by 
Conger and 
Kanungo) 
  
+ Encouragement to participate in 
decision‐making, and to bring their 
spouse/significant other(s) to the 
treatment consultation; N=30 
SCREENING AND TREATMENT 
Wilt, 2001 [86]  USA 
 
RCT, parallel 
Oct to Nov 1998 
Funding: n.r. 
Primary care clinic at 
a Veterans' Affair 
Medical Center, 1 
Men of at least 50 years of 
age, attending a primary care 
clinic at a Veterans' Affair 
Medical Center 
n.r.  1) 7th grade Fleisch‐Kincaid 
Question and answer two‐sided 
printed sheets; N=275 
1) Usual care (control) alone; 
N=275 
Unclear/n.r. 
 
 
 
 
